01 April 2021
Pictured: DMX-200 included in a global feasibility/Phase 3 study in patients with COVID-19 pneumonia. Image by Shutterstock (under Dimerix's license).
In October 2020, clinical-stage biopharmaceutical company Dimerix was awarded BTB funding to support development and clinical evaluation of DMX-200, a new treatment for respiratory complications resulting from COVID-19.
The drug candidate was selected for inclusion in the global REMAP CAP study endorsed by the WHO (an investigator-led feasibility/Phase 3 study) for patients with Acute Respiratory Distress Syndrome associated with COVID-19.
This week, the company announced it is poised to commence the REMAP-CAP clinical trial study, with finished product to support the study available and ready for recruitment throughout Europe.
“REMAP-CAP is an international adaptive platform trial investigating the best treatments for patients with community acquired pneumonia, including COVID-19. We are delighted to be working with such a high calibre team towards helping reduce the burden of COVID-19 in patients globally, as well as address respiratory complications commonly associated with pneumonia more broadly,” said Dr Nina Webster, CEO & Managing Director of Dimerix.
DMX-200 therapy is aimed at reducing damage from inflammatory immune cells by blocking their signalling and limiting subsequent movement. Patients hospitalised with COVID-19 commonly have acute lung dysfunction due to the immune response to the virus.
Global experts see DMX-200 as a compelling treatment option to limit inflammation in the lungs during infection of the SARS-CoV2 virus.
Dimerix will report on progress as key milestones are met. Importantly, if DMX-200 does show benefit in patients with COVID-19, it may also show benefit in respiratory complications associated with other infections too, such as pneumonia and influenza. Thus, this provides an opportunity that could extend well beyond the impact of COVID-19.
Find out more about Melbourne-based Dimerix Limited (ASX:DXB) on their website.